The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2016 | Panel discussion on mantle cell lymphoma
Simon Rule, MD of Plymouth University, Plymouth, UK discusses mantle cell lymphoma (MCL) with Constantine Tam, MBBS, MD of Peter MacCallum Cancer Center, Melbourne, Australia and Mary Callanan, PhD of Joseph Fourier University, Grenoble, France. Dr Tam discusses groups of patients with poor outcome and the AIM trial of venetoclax (ABT-199) and ibrutinib (NCT02471391); while results are preliminary, they are seeing high rates of complete remission (CR) and minimal residual disease (MRD) clearance. Dr Callanan discusses MRD assessment in clinical trials as well as the Lyma trial and autologous transplantation (NCT00921414). Prof. Rule then talks about ibrutinib, relapse and chemotherapy. Finally, they discuss treatment duration and how decide when to stop treatment.
Recorded at the 2016 International Workshop on Non-Hodgkin Lymphoma (iwNHL) meeting held in San Diego, CA.
